CEO Moshe Mizrahy’s Group Offers to Take InMode Private at $16.20 Per Share
Board forms special committee to evaluate the offer.
Already have an account? Sign in.
Board forms special committee to evaluate the offer.
Her first major trades since early 2026.
Viking Therapeutics advances its obesity portfolio with the start of a Phase 1 trial for VK3019, a novel dual amylin and calcitonin receptor agonist. Analyst sees major potential.
The firm initiated Overweight coverage citing strong divesiran Phase 2 potential and 160%+ upside.